Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Flextronics International Ltd. (NASDAQ: FLEX) shares increased 0.54 percent to close at $9.25 a share Wednesday. The stock traded between $9.11 and $9.25 on volume of 3.32 million shares traded. Analysts at Goldman Sachs have recently initiated coverage on the company with a "neutral" rating. Shares of Flextronics International have gained approximately 49.0 percent year-to-date.
Find out more about Flextronics International including full access to the free equity report at:
FMC Technologies, Inc. (NYSE: FTI) shares increased 1.39 percent to close at $56.99 a share Wednesday. The stock traded between $55.97 and $57.21 on volume of 1.83 million shares traded. Analysts at Capital One have recently upgraded the company’s rating to "add" from neutral and have also raised its price target to $64.00. Shares of FMC Technologies have gained approximately 33.0 percent year-to-date.
Find out more about FMC Technologies including full access to the free equity report at:
Healthways, Inc. (NASDAQ: HWAY) shares declined 2.46 percent to close at $18.23 a share Wednesday. The stock traded between $18.14 and $18.62 on volume of 960,639 shares traded. Analysts at Stephens have recently initiated coverage on the company with an "underweight" rating and a price target of $12.00. Shares of Healthways have gained approximately 70.0 percent year-to-date.
Find out more about Healthways including full access to the free equity report at:
Osiris Therapeutics, Inc. (NASDAQ: OSIR) shares increased 12.37 percent to close at $18.80 a share Wednesday. The stock traded between $17.14 and $19.65 on volume of 1.52 million shares traded. Analysts at Piper Jaffray have recently upgraded the company’s rating to "overweight" from “neutral”. Shares of Osiris Therapeutics have gained approximately 110.0 percent year-to-date.
Find out more about Osiris Therapeutics including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...